journal article·2023-05Open access

A Dendrimer Peptide (KK2DP7) Delivery System with Dual Functions of Lymph Node Targeting and Immune Adjuvants as a General Strategy for Cancer Immunotherapy

Rui Zhang, Lin Tang, Yusi Wang, Yaomei Tian, Siwen Wu, Bailing Zhou, Chunyan Dong, Binyan Zhao, Yuling Yang, Daoyuan Xie, Li Yang

Advanced Science· Volume 10· Issue 15

Abstract

Abstract The clinical efficacy of personalized cancer vaccines still needs to be improved due to their insufficient immune effect. The development of innovative adjuvants and lymph node‐targeted delivery systems is the key to improving the clinical efficacy of personalized vaccines. However, there is still a lack of an adjuvant delivery system that is simple in preparation and capable of mass production and integrates adjuvant and lymph node targeted delivery functions. Here, this work reports that a simple dendrimer polypeptide (KK2DP7) nanoparticle enhances the immune efficacy of an OVA/neoantigen‐based vaccine. Due to its multiple functions as a delivery vehicle, immune adjuvant, and facilitator of dendritic cell migration, KK2DP7 efficiently increases the efficiency of antigen uptake and cross‐presentation by antigen‐presenting cells (APCs) and delivers antigens to lymph nodes via APCs. Strikingly, the antitumor effect of KK2DP7/OVA is superior to that of commonly used adjuvants such as poly(I:C), CpG, and aluminum adjuvant combined with OVA. Furthermore, KK2DP7/OVA combined with anti‐PD‐1 antibody is able to prevent tumor recurrence in a postoperative recurrent tumor model. Thus, KK2DP7‐based cancer vaccines alone or in combination with immune checkpoint blockade therapies to treat tumors or postoperative tumor recurrence are a powerful strategy to enhance antitumor immunity.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Immunotherapy and Immune Responses · RNA Interference and Gene Delivery · Cancer Immunotherapy and Biomarkers

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Biotherapy and Cancer Center West China Hospital Sichuan University and Collaborative Innovation Center for Biotherapy Chengdu 610041 China

Funding

National Natural Science Foundation of China

References (37)

Show source-provided references
1. 10.1038/s41578-019-0110-710.1038/s41578-019-0110-7 ↗
2. 10.1016/j.jconrel.2017.08.00910.1016/j.jconrel.2017.08.009 ↗
3. 10.1021/acsbiomaterials.1c0127410.1021/acsbiomaterials.1c01274 ↗
4. 10.1007/s00018-021-03842-610.1007/s00018-021-03842-6 ↗
5. 10.1186/s12951-021-01146-210.1186/s12951-021-01146-2 ↗
6. 10.1016/j.biomaterials.2020.12020810.1016/j.biomaterials.2020.120208 ↗
7. 10.1002/adma.20200600710.1002/adma.202006007 ↗
8. 10.1128/AAC.02823-1410.1128/AAC.02823-14 ↗
9. 10.1016/j.biomaterials.2020.11985210.1016/j.biomaterials.2020.119852 ↗
10. 10.1021/acs.molpharmaceut.0c0125310.1021/acs.molpharmaceut.0c01253 ↗
11. 10.1038/nature1297810.1038/nature12978 ↗
12. 10.1097/01.cji.0000171290.78495.6610.1097/01.cji.0000171290.78495.66 ↗
13. 10.1007/s00262-008-0489-210.1007/s00262-008-0489-2 ↗
14. 10.1002/wnan.122710.1002/wnan.1227 ↗
15. 10.1016/j.critrevonc.2016.09.00210.1016/j.critrevonc.2016.09.002 ↗
16. 10.1038/nature1432010.1038/nature14320 ↗
17. 10.1016/j.critrevonc.2017.01.01110.1016/j.critrevonc.2017.01.011 ↗
18. 10.1186/s43556-021-00058-910.1186/s43556-021-00058-9 ↗
19. 10.1038/nri325410.1038/nri3254 ↗
20. 10.1016/j.biomaterials.2022.12148910.1016/j.biomaterials.2022.121489 ↗
21. 10.1038/nri141310.1038/nri1413 ↗
22. 10.1007/s00262-019-02448-z10.1007/s00262-019-02448-z ↗
23. 10.1016/j.biomaterials.2020.11985210.1016/j.biomaterials.2020.119852 ↗
24. 10.1038/s41591-020-01206-410.1038/s41591-020-01206-4 ↗
25. 10.1038/s41698-022-00279-310.1038/s41698-022-00279-3 ↗
26. 10.1038/s41392-020-00448-510.1038/s41392-020-00448-5 ↗
27. 10.1016/j.vaccine.2019.04.05510.1016/j.vaccine.2019.04.055 ↗
28. 10.1016/j.addr.2021.11391410.1016/j.addr.2021.113914 ↗
29. 10.1021/acsbiomaterials.1c0127410.1021/acsbiomaterials.1c01274 ↗
30. 10.1016/j.smim.2021.10153410.1016/j.smim.2021.101534 ↗
31. 10.1016/j.jconrel.2014.04.05110.1016/j.jconrel.2014.04.051 ↗
32. 10.1152/physrev.00037.201110.1152/physrev.00037.2011 ↗
33. 10.1023/A:101588081932810.1023/A:1015880819328 ↗
34. 10.1007/s11095-006-9064-810.1007/s11095-006-9064-8 ↗
35. 10.1038/nmat482210.1038/nmat4822 ↗
36. 10.1016/j.jconrel.2020.08.02310.1016/j.jconrel.2020.08.023 ↗
37. 10.1038/s41565-020-00781-410.1038/s41565-020-00781-4 ↗